|Application ||WB, E|
|Calculated MW||52000 Da|
|Antigen Region||53-80 aa|
|Other Names||Nyctalopin, NYX, CLRP|
|Target/Specificity||This NYX antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 53-80 amino acids from the N-terminal region of human NYX.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||NYX Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
|Tissue Location||Expressed in kidney and retina. Also at low levels in brain, testis and muscle. Within the retina, expressed in the inner segment of photoreceptors, outer and inner nuclear layers and the ganglion cell layer.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The product of this gene belongs to the small leucine-rich proteoglycan (SLRP) family of proteins. Defects in this gene are the cause of congenital stationary night blindness type 1 (CSNB1), also called X-linked congenital stationary night blindness (XLCSNB). CSNB1 is a rare inherited retinal disorder characterized by impaired scotopic vision, myopia, hyperopia, nystagmus and reduced visual acuity. The role of other SLRP proteins suggests that mutations in this gene disrupt developing retinal interconnections involving the ON-bipolar cells, leading to the visual losses seen in patients with complete CSNB. [provided by RefSeq].
?Leroy, B.P., et al. Br J Ophthalmol 93(5):692-696(2009)
?Zhang, Q., et al. Mol. Vis. 13, 330-336 (2007)
?Morgans, C.W., et al. Eur. J. Neurosci. 23(5):1163-1171(2006)
?Xiao, X., et al. J. Hum. Genet. 51(7):634-640(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.